tbuckley/cabot-search huggingface dataset:
The Relationship Between Syndrome X and Left Ventricular Hypertrophy: The Impact Of Different Methods of Adjusting Left Ventricular Mass.
Authors: Heidi M Guyer, Manel Pladevall, Aina M Yanez, Carles Falces, Josep Sadurni, Anna Ribes, Carles Pare
Journal: Circulation (2001)

P67 Left ventricular hypertrophy is associated with the various elements of the insulin resistance syndrome (Syndrome X) including insulin resistance, hypertension, diabetes, dyslipidemia and obesity. There is no current consensus on the correct method of adjusting left ventricular mass (LVM). Objective: To determine the variation in the relationship between left ventricular hypertrophy (LVH)and Syndrome X when LVM is adjusted for height, height 2.7 and body surface area (BSA) in a population based study. Methods:LVM was measured echocardiographically in 442 participants aged 35 to 65 years. Results: The prevalence of LVH ranged from 15.6% to 33.9% depending on adjustment method. The correlation between LVH and Syndrome X components varied by adjustment criteria and by sex. In men, LVH was only correlated with blood pressure and obesity measurements. In women, LVH was correlated with all Syndrome X components except HDL cholesterol. Regardless of adjustment method, women with Syndrome X were more likely to have LVH than those without Syndrome X, although the magnitude of the relationship varied by LVM adjustment (LVM/height 2.7 : OR 16.6, 95% CI: 6.7 41.1; LVM/BSA: OR 5.8, 95% CI: 2.6-12.9). In men, the relationship between Syndrome X and LVH was significant when LVM was adjusted for height 2.7 (OR 3.0, 95% CI: 1.4-6.7) but not when adjusted for BSA (OR 1.2, 95% CI: 0.4-3.5). Conclusions:Both the prevalence of LVH and the relationship between LVH and Syndrome X are dependent on the method used to adjust LVM. When LVM is adjusted for height 2.7 , LVH is more prevalent and the relationship with Syndrome X is stronger than when adjusted for BSA. Regardless of adjustment method, the relationship between Syndrome X and LVH is much stronger in women than men. The LVM adjustment method employed is important to take into account both in epidemiological studies and clinical practice.
Sleep Medicine
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The mysterious "urethral syndrome".
Journal: BMJ (1991)

Bleeding peptic ulcers SIR,-Professor Stephen Bown is correct to remark on the recent advances in endoscopic treatment of bleeding peptic ulcers.With the emerging evidence of the efficacy of endoscopic techniques, and with an aging population, who tolerate laparotomv badly, these techniques should be more widely available.Professor Bown discusses the evidence of their efficacy in a traditional narrative manner, and I am confident that his conclusions are correct.He has not, however, explored the results of three relevant meta-analyses.24Two of these studies were reviewed at a workshop on meta-analysis in gastrointestinal haemorrhage held in Newcastle, New South Wales, in September last year.'This was a satellite meeting of the World Congress of Gastroenterology.The table summarises the results presented at the workshop.Several conclusions can be drawn.Firstly, evidence of benefit seems to be greatest in the case of laser treatments, with both meta-
Availability of New Rabies Vaccine for Human Use
Journal: JAMA (1998)

On October 20, 1997, the Food and Drug Administration licensed a new rabies vaccine for both pre-exposure and postexposure prophylactic use in humans. This purified chick embryo cell culture (PCEC) vaccine (RabAvert) is manufactured by Chiron Behring GmbH and Company. The addition of PCEC to the current products available for pre-exposure and postexposure prophylactic use in humans allows for greater flexibility in treatment choices for the vaccination candidate who develops a sensitivity to one of the other available vaccines. Although derived from chick embryo cells, antibodies to chick cell proteins were not detected in recipients of the vaccine.
ATROPINE DIARRHEA
Authors: William Allan
Journal: JAMA (1928)

Sollmann,<sup>1</sup>in discussing the action of atropine, says: "Ordinary therapeutic doses relax the intestines in man and rabbits (Katsch, 1913; Hirz, 1913). In cats, they may increase peristalsis (Magnus). It is conceivable that this also occurs in man in some conditions." <h3>REPORT OF CASE</h3> A woman, aged 30, the wife of a physician, was referred to me after the hay-fever season. She had sneezed excessively all the year, had been troubled with constipation and sour stomach for a month, and for three nights had had a dry, tickling cough. Nothing abnormal was found on physical examination: the sinuses were clear and the blood and urine normal. She was given magnesia and 15 drops of belladonna, three times a day, and promptly developed diarrhea with cramping. The magnesia was stopped without influencing the diarrhea. When the belladonna was stopped, the diarrhea and cramping disappeared over night. When
Invasive fungal infections (IFI) in patients (pts) receiving hyper-CVAD
Authors: M. E. Cabanillas, G. Mattiuzzi, D. Thomas, K. Vu, G. Ossa, G. Garcia-Manero, J. Cortes, F. Giles, S. O'Brien, H. Kantarjian
Journal: Journal of Clinical Oncology (2004)
Corrections to “Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer”
Authors: Y. Wu, M.M. Amonkar, B.H. Sherrill, J. O'Shaughnessy, C. Ellis, J. Baselga, K.L. Blackwell, H.J. Burstein
Journal: Annals of Oncology (2019)

Ann Oncol 2011; 22: 2582–2590 (doi: 10.1093/annonc/mdr014) In the original article, the disclosure was incomplete. This has now been updated to add the statement for J. Baselga: JB is the consultant and on the advisory board for Roche and Novartis. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancerAnnals of OncologyVol. 22Issue 12PreviewProgression-free survival (PFS) was significantly longer for the lapatinib plus trastuzumab (L+T) arm than for L alone in a phase III, randomized, open-label study of women with human epidermal growth factor receptor 2 positive metastatic breast cancer who had documented progression on at least one T-containing regimen in the metastatic setting. This analysis focused on impact of treatments on health-related quality of life (HRQOL). Full-Text PDF Open Archive
The Madness of Sport
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Omission and Incorrect Color Reproduction
Authors: William Wadland, Carole Keefe, Margaret Thompson, Mary Noel
Journal: JAMA (2000)

seling session with simulated patients.Two independent observers rated the sessions using a 10-point checklist based on the Agency for Health Care Policy and Research (now called the Agency for Healthcare Research and Quality [AHRQ]) criteria.Student scores ranged from 6.5 to 10.Only 10% of the scores were below 8, with a high level of interobserver agreement (r = 0.847).Our data show that students can readily learn cessation counseling skills and such performance can be reliably evaluated.
Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity
Authors: Jonathan Lam, Christopher A. Nelson, F. Patrick Ross, Steven L. Teitelbaum, Daved H. Fremont
Journal: Journal of Clinical Investigation (2001)

RANK, the receptor activator of NF-κB, and its ligand RANKL (initially termed TRANCE, also termed ODF and OPGL), are a TNF superfamily receptor-ligand pair that govern the development and function of osteoclasts, lymphoid tissue, and mammary epithelium. While TNF family cytokines share a common structural scaffold, individual receptor-ligand pairs associate with high specificity. Given the low level of amino acid conservation among members of the TNF superfamily, the means by which these molecules achieve specificity cannot be completely understood without knowledge of their three-dimensional structures. To determine the elements of RANKL that mediate RANK activation, we have crystallized the ectodomain of murine RANKL and solved its structure to a resolution of 2.6 Å. RANKL self-associates as a homotrimer with four unique surface loops that distinguish it from other TNF family cytokines. Mutagenesis of selected residues in these loops significantly modulates RANK activation, as evidenced by in vitro osteoclastogenesis, thereby establishing their necessity in mediating the biological activities of RANKL. Such structural determinants of RANKL-RANK specificity may be of relevance in the pharmacologic design of compounds to ameliorate osteopenic disorders of bone.
P103 Metabolic profiling of the rat liver after chronic ingestion of -naphthylisothiocyanate using in vivo and ex vivo magnetic resonance spectroscopy
Authors: B. S. Solanky, G. J. Sanchez-Canon, J. F. L. Cobbold, S. D. Taylor-Robinson, J. D. Bell, C. L. Scudamore, J. C. Holder, P.-W. So, I. J. Cox
Journal: Gut (2011)

<h3>Introduction</h3> Hepatobiliary injury, associated with intrahepatic cholestasis and biliary hyperplasia, is a commonly encountered adverse effect in man in response to certain drugs and toxins. Some human diseases affecting the biliary tree can be modelled in rats by ingestion of the hepatobiliary toxin, α-naphthylisothiocyanate (ANIT). The ability to detect biliary hyperplasia and associated hepatobiliary injury non-invasively, by longitudinal liver specific assessment, would be of value in the development of novel therapies and aid towards the understanding of hepatic pathophysiological processes. <h3>Aim</h3> To investigate the use of in vivo hepatic phosphorus-31 (<sup>31</sup>P) magnetic resonance spectroscopy (MRS) to provide potential biomarkers for hepatobiliary injury linked to biliary hyperplasia in the ANIT-fed rat model and to investigate longitudinal changes according to dose over a 2-week time period. <h3>Method</h3> All experiments were performed in compliance with the UK Animals (Scientific Procedures) Act 1986. Chronic hepatobiliary dysfunction was investigated in rats fed a diet supplemented with ANIT at three doses (ANIT_0.025%, ANIT 0.04% and ANIT_0.05%) for 2 weeks using in vivo hepatic <sup>31</sup>P MRS. In vivo <sup>31</sup>P MRS data collected at baseline and weeks 1 and 2 for each of the three ANIT groups were compared to results from corresponding pair-fed controls (six groups of n=8 per group). Serum was collected for clinical chemistry and tissue for both histology and ex vivo <sup>1</sup>H magic angle spinning (MAS) MRS after sacrifice at 2 weeks. <h3>Results</h3> In vivo <sup>31</sup>P MRS showed phosphodiesters (PDE), relative to total phosphorus signal (tPh), were significantly increased (p&lt;0.05) after 1 and 2 weeks in both ANIT 0.05% and ANIT 0.04% groups relative to controls, but an increase in phosphomonesters (PME)/tPh was observed in the ANIT 0.05% group only. Clinical chemistry findings confirmed chronic liver injury to some extent at all ANIT dosages. Histological findings included a dose related increase in both severity of biliary hyperplasia and focal hepatocellular necrosis with increasing doses of ANIT. Ex vivo <sup>1</sup>H MAS MRS findings supported the in vivo MRS findings in that the peak assigned to glycerophosphocholine and phosphocholine (GPC+PC) was relatively increased in the ANIT 0.05% and ANIT 0.04% groups (p&lt;0.05) relative to the respective control groups. <h3>Conclusion</h3> ANIT-induced moderate hepatobilliary dysfunction was associated with a dose dependent increase in phosphodiesters in vivo and choline-containing phosphodiesters and phosphomonoesters ex vivo. Such data suggest a role for magnetic resonance spectroscopy techniques as a non-invasive way of investigating hepatobilliary dysfunction.
A double-blind, randomized placebo-controlled, phase II study of maintenance enzastaurin (ENZ) with 5-FU/leucovorin (LV) plus bevacizumab (BV) following first-line therapy for metastatic colorectal cancer (mCRC).
Authors: R. A. Wolff, W. Schepp, M. DiBartolomeo, A. Hossain, C. Stoffregen, S. Nicol, V. Heinemann
Journal: Journal of Clinical Oncology (2011)

501 Background: Maintenance therapy is designed to maximize progression-free survival (PFS) and minimize toxicity in advanced CRC. ENZ is an oral serine/threonine kinase inhibitor that targets PKC-b and the AKT/PI3K pathway. Preclinical studies demonstrated synergistic antitumor effects when ENZ was combined with BV. In phase I studies, the combination was well tolerated. This phase II study assessed ENZ with 5-FU/LV plus BV as maintenance therapy for mCRC. Methods: Patients had locally advanced or mCRC, and completed 6 cycles of first-line chemotherapy ≤4 wks prior to randomization. Arm A received a loading dose of ENZ 1,125 mg, followed by 500 mg/d subsequent doses. Arm B received placebo. Both groups received 5-FU/LV (LV 400 mg/m 2 IV, 5-FU 400 mg/m 2 bolus, 5-FU 2,400 mg/m 2 IV) plus BV 5 mg/kg IV, every 2 wks. Patients were treated with 5-FU/LV plus BV plus either ENZ or placebo until disease progression or for 1 yr. Primary endpoint was PFS from randomization. Secondary endpoints were overall survival (OS) from randomization, and OS and PFS from start of first-line therapy. Analysis was done after 50 events (objective or clinical progression). Results: 58 patients were randomized to Arm A (57 treated), 59 to Arm B (58 treated). 82 (70.1%) patients discontinued treatment (Arm A, 42 [72.4%]; Arm B, 40 [67.8%]), the majority due to disease progression. Median cycles were 9 in Arm A, 10 in Arm B. Median PFS in months was 5.8 in Arm A and 8.1 in Arm B (hazard ratio [HR]=1.35, 95% CI: 0.84, 2.16; protocol specified one-sided test, p=0.896). Median OS was not calculable due to high censoring (77.6% in Arm A and 91.5% in Arm B). Median PFS in months from start of first-line therapy was 8.9 in Arm A and 11.3 in Arm B (HR=1.39, 95% CI: 0.86, 2.23; one-sided, p=0.913). More patients developed thrombosis or embolism (TE), including pulmonary embolism, on Arm A (5 [8.8%] patients had grade 3 and 5 [8.8%] grade 4 TE) compared with Arm B (no grade 3 and 1 [1.7%] grade 4 TE). Conclusions: ENZ did not demonstrate an advantage in PFS compared to BV-based therapy alone. Further development of maintenance therapy with ENZ is not recommended for mCRC. [Table: see text]
ANNOUNCEMENTS: Fellowships and Grants
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article ANNOUNCEMENTS: Fellowships and Grants Get access JNCI: Journal of the National Cancer Institute, Volume 83, Issue 9, 1 May 1991, Pages 655–656, https://doi.org/10.1093/jnci/83.9.655 Published: 01 May 1991
Apalutamide OK'd for Some Prostate Cancers
Journal: Cancer Discovery (2018)

The FDA approved the antiandrogen apalutamide for the treatment of men with nonmetastatic, castration-resistant prostate cancer, the first drug for these patients greenlighted by the agency. Data from the definitive trial of apalutamide, presented at the 2018 Genitourinary Cancers Symposium, showed that the drug prolonged metastasis-free survival by more than 2 years compared with placebo. Data on the related drug enzalutamide, also presented at the symposium, showed that that drug led to dramatic improvements in metastasis-free survival, too.
Artist's Name Misspelled
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply
Authors: C.M.E.Rowland Payne, J.D. Wilkinson, P.H. McKee, W. Jurecka, M.M. Black
Journal: British Journal of Dermatology (1986)

Journal Article Reply Get access C.M.E.Rowland Payne, C.M.E.Rowland Payne Laboratoire de Recherche Bioclinique en Dermatologie, Université Paris Val‐de‐Marne, Hôpital Henri Mondor, Créteil, France Search for other works by this author on: Oxford Academic Google Scholar J.D. Wilkinson, J.D. Wilkinson Laboratoire de Recherche Bioclinique en Dermatologie, Université Paris Val‐de‐Marne, Hôpital Henri Mondor, Créteil, France Search for other works by this author on: Oxford Academic Google Scholar P.H. McKee, P.H. McKee Laboratoire de Recherche Bioclinique en Dermatologie, Université Paris Val‐de‐Marne, Hôpital Henri Mondor, Créteil, France Search for other works by this author on: Oxford Academic Google Scholar W. Jurecka, W. Jurecka Laboratoire de Recherche Bioclinique en Dermatologie, Université Paris Val‐de‐Marne, Hôpital Henri Mondor, Créteil, France Search for other works by this author on: Oxford Academic Google Scholar M.M. Black M.M. Black Laboratoire de Recherche Bioclinique en Dermatologie, Université Paris Val‐de‐Marne, Hôpital Henri Mondor, Créteil, France Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 114, Issue 4, 1 April 1986, Pages 521–522, https://doi.org/10.1111/j.1365-2133.1986.tb02870.x Published: 01 April 1986
SURGERY OF THE ADRENAL CORTEX
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New IOM report links agent orange exposure to risk of birth defect in Vietnam vets' children
Authors: J. Stephenson
Journal: JAMA (1996)

NEW EVIDENCE reveals a tentative link between exposure to chemical defoliants that were used in the Vietnam War and an increased risk of spina bifida in veterans' children, according to a recently issued report by the National Academy of Sciences' Institute of Medicine (IOM). The congressionally mandated report,<i>Veterans and Agent Orange: Update 1996</i>, is the second in a series of biennial reassessments of the health effects of Agent Orange and other herbicides. In addition to noting limited or suggestive evidence of an increased risk of the birth defect in exposed veterans' children, it said that new studies confirm the 1994 report's finding that there is sufficient evidence that exposure to these chemicals is linked with soft tissue sarcoma, non-Hodgkin's lymphoma, Hodgkin's disease, and chloracne. The report also described "limited or suggestive" evidence, based on studies of occupational exposure to herbicides or dioxin outside of Vietnam, that exposure may be